Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

Table 4 Correlations of the biomarkers and the neuropsychological tests and self-reported questionnaires

	Patients VEGFR TKI		Patient controls		Patients VEGFR TKI		Patient controls		Patients VEGFR TKI		Patient controls		Patients VEGFR TKI		Patient controls
	CRP				ESR				LDH				VEGF
	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P
*Neuropsychological tests*
Learning & memory	-0.427	0.019			-0.410	0.030
Working memory
Episodic memory	-0.432	0.017
Semantic memory
Attention & concentration					-0.440	0.019
Alertness
Sustained attention
Executive functions					-0.376	0.049
Response generation
Response inhibition
Mental flexibility
Problem solving
*Self-reported questionnaires*
SLC90-R total score															-0.626	0.004
Anxiety															-0.526	0.021
Depression															-0.518	0.023
Sleep disturbance
Agoraphobia
Somatization															-0.476	0.039
Cognitive-performance difficulty															-0.540	0.017
Interpersonal sensitivity and paranoid ideation															-0.638	0.003
Anger-hostility															-0.729	0.000
CFQ total score															-0.754	0.000
BDI-II total score	0.379	0.039			0.378	0.047			0.464	0.010					-0.622	0.004
CIS20r total score
CIS fatigue
CIS motivation
CIS concentration															-0.466	0.045
CIS activation

Correlations between the biomarkers and the Neuropsychological Tests and Self-report Questionnaires in the VEGFR TKI patients and the patient controls. Only the significant correlations are listed in the table. r = Pearson correlation coefficient.

ISSN: 1471-2407